Loading stock data…
Pulse Biosciences, Inc (PLSE)
$48.79-4.45 (-8.36%)
Market ClosedLast close Sep 8
Pulse Biosciences, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Pulse Biosciences, Inc. in the Healthcare sector is trading at $48.79 with a market capitalization of $3.5B. Wall Street consensus targets $45.25 (4 analysts), implying a -7.3% move over the next 12 months. The stock is currently near its 52-week high of $55.37, remaining 101.1% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply -7.3% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $434,000↑ | $401,000↑ | $264,000↑ | $86,000 | $0 |
| Gross Profit | $161,000↑ | $31,000↑ | $4,000↑ | -$193,000 | $0 |
| Operating Income | -$25.27M↓ | -$19.15M↓ | -$18.25M↑ | -$20.37M↓ | -$20.27M |
| Net Income | -$24.66M↓ | -$18.58M↓ | -$17.43M↑ | -$19.39M↓ | -$19.17M |
Peer Comparison
JNJUNHPFE
Fundamentals
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.48B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.63
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-80.46%
Volume
Today's trading volume
769,172
Recent News
Pulse Biosciences (PLSE) Stock Looks Pricey On Book Value Yet Strong On Returns
Pulse Biosciences has delivered a very strong share price run, with recent enthusiasm around its atrial fibrillation program now sitting against valuation checks that point to a stock that screens expensive rather than cheap. Over the past 3 years, Pulse Biosciences has returned about 431.5%, which puts a lot of expectation into the current price. Progress in the NANOPULSE-AF pivotal clinical study and advancing regulatory work can support hopes for future commercialisation, while any delay...
Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform
Pulse Biosciences (NASDAQ:PLSE) is positioning its nanosecond pulsed field ablation technology as a potential next-generation treatment platform for atrial fibrillation and other conditions, President, CEO and Co-Chairman Paul LaViolette said during the Canaccord Genuity 46th Annual Global Growth Co
Pulse Biosciences (PLSE) Prices A $75 Million Offering, Is The Stock Fully Valued?
Pulse Biosciences (PLSE) is back in focus after reporting wider second quarter losses and announcing a $75 million at the market follow on equity offering, a combination that directly affects existing shareholders. See our latest analysis for Pulse Biosciences. The recent earnings release and the $75 million at the market offering have come after a strong run in Pulse Biosciences' share price, with a 30 day share price return of 55.30% and a 90 day share price return of 73.92%. Over a longer...
Pulse Biosciences (PLSE) Q2 2026 Earnings Call Transcript
NANOPULSE-AF enrollment hit halfway point ahead of schedule with 82 patients.
Pulse Biosciences, Inc. Q2 2026 Earnings Call Summary
Moby summary of Pulse Biosciences, Inc.'s Q2 2026 earnings call